secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013788
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical reports FY2025 net income $5.0M vs loss $16.5M; revenue $134M (+14% YoY)
--------------------------------------------------------------------------------

- Full-year 2025 revenue $134.0M (+14% YoY); net income $5.0M ($0.03 diluted EPS) vs net loss $16.5M in 2024.
- Q4 2025 revenue $32.4M (+3% YoY); net income $0.1M vs net loss $3.2M; non-GAAP adjusted EBITDA $1.9M vs $0.4M.
- Completed sale of non-core Coflex/CoFix assets and international hardware to Companion Spine for $21.4M cash.
- Launched nanOss Strata synthetic bone graft and CollagenX bovine collagen product; total cash $17.3M at Dec 2025 + $10.5M received Feb 2026.
- FY2026 revenue guidance $95M-$99M reflecting divestiture impact and cessation of license revenue; expects free cash flow positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer